Comparative Pharmacology
Head-to-head clinical analysis: PEPCID PRESERVATIVE FREE versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID PRESERVATIVE FREE versus PEPCID RPD.
PEPCID PRESERVATIVE FREE vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, inhibiting gastric acid secretion.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
20 mg intravenously over at least 2 minutes or as an infusion over 15-30 minutes every 12 hours; alternatively, 20 mg orally once or twice daily.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
2.5-3.5 hours (normal renal function); prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: dose adjustment required in renal insufficiency.
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Renal (65-70% unchanged by tubular secretion); minor biliary/fecal elimination (<30%). Clearance correlates with creatinine clearance.
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist